# US 2012/0252799 A1 · Heterocyclic aromatic compounds useful as growth hormone secretagogues

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252799 A1
- Document ID: US20120252799A1
- Status: Published application
- Kind: A1
- Application number: 13/493,448
- Filed: 2012-06-11
- Published: 2012-10-04
- Earliest claimed: 2002-09-04
- Assignees: Bristol-Myers Squibb Company
- Inventors: Guixue Yu; Jun Li; William R. Ewing; Richard B. Sulsky; James J. Li; Joseph Anthony Tino
- Web page: https://patentgrep.com/patent/US20120252799A1

## CPC

- C07D 487/04: Ortho-condensed systems
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/00: Drugs for disorders of the endocrine system
- A61P 5/06: of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 13/00: Drugs for disorders of the urinary system
- A61P 13/12: of the kidneys
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/10: for osteoporosis
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/20: Hypnotics; Sedatives
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 31/18: for HIV
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/04: Immunostimulants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 231/56: Benzopyrazoles; Hydrogenated benzopyrazoles
- C07D 261/20: condensed with carbocyclic rings or ring systems
- C07D 471/04: Ortho-condensed systems
- C07D 513/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Novel heterocyclic aromatic compounds are provided that are useful in stimulating endogenous production or release of growth hormone, said compounds having the general structure of formula I wherein R1, R1′, R2, R3, R4, Xa, Y, Z and n are as described herein. The compounds provided herein are useful in treating obesity, osteoporosis (improving bone density) and in improving muscle mass and muscle strength.

## Claims

### Claim 1

A method for treating or delaying the progression or onset of HIV wasting syndrome, muscular atrophy, lipodistrophy, long term critical illness, osteoporosis, sarcopenia, fraility or ARFD in the elderly, renal disease, anorexia, sleep disorders, depression, Syndrome X, congestive heart failure, cardiac myopathy, cardiac dysfunction associated with valvular disease and cachexia which comprises administering to a mammalian patient in need of treatment a therapeutically effective amount of a compound according to Formula I
wherein
R1 is a substituted or unsubstituted alkyl;
R2 is a substituted or unsubstituted functional group selected from the group consisting of hydrogen, alkyl, aryl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heterocycle, alkoxyalkyl, arylalkyloxyalkyl, aryloxyalkyl, heteroaryl, cycloalkylalkoxyalkyl, heteroarylalkyl and heterocycloalkyl;
R3 and R4 are each independently a substituted or unsubstituted functional group selected from the group consisting of hydrogen and alkyl, or R3 and R4 taken together can form a 4 to 7 membered heterocyclic ring, or one or more of R3 and R4 can be taken together with Y to form a 4 to 7 membered heterocyclic ring;
R1′ is a substituted or unsubstituted functional group selected from the group consisting of hydrogen, alkyl, cycloalkyl, heterocycle, aryl and heteroaryl;
Y is a linking group selected from the group consisting of alkylene, alkenylene, alkynylene, arylene and heteroarylene, said linking group may optionally be substituted with one or more functional group selected from the group consisting of alkyl, aryl, cycloalkyl, heterocycle, alkoxyalkyl, heteroaryl, arylalkyl, arylalkyloxyalkyl, aryloxyalkyl, cycloalkylalkoxyalkyl, heteroarylalkyl, —OR5, —OC(O)R5, —CF3, —OCF3, —N(R5)C(O)R5′ and —NR5R5′;
R5 and R5′ for each occurrence are each independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, heterocycle and aryl, wherein R5 and R5′ for each occurrence may optionally be substituted with one or more Rb;
Rb for each occurrence is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, halogen, cyano, —CN, aryl, arylalkyl, arylalkenyl, arylalkynyl, cycloalkyl, alkoxy, alkoxyalkyl, aryloxy, aryloxyalkyl, heterocycle, heteroaryl, heteroarylalkyl, —OR2, —NR5R5′, —CF3, —SO2R6, —OC(O)R5, —SO2NR6R6′, —(CH2)mR8 and R9;
R6 and R6′ for each occurrence are each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, alkylthioalkyl, alkoxyalkyl, aryl, arylalkyl, heterocycle, heteroaryl, heteroarylalkyl, heterocycloalkyl and cycloalkyl, wherein R6 and R6′ for each occurrence may optionally be substituted with 1 to 3 substituents selected from the group consisting of halogen, OR2, alkoxy, heterocycloalkyl, —NR5C(O)NR5R5′, —C(O)NR5R5′, —NR5C(O)R5′, —CN, —NR5SO2R5′, —OC(O)R5, —SO2NR5R5′, —SOR7, —COOH and —C(O)OR7, or R6 and R6′ taken together can be cyclized to form —(CH2)qX(CH2)s—, which may optionally be substituted with 1 to 3 substituents selected from the group consisting of halogen, OR2, alkoxy, heterocycloalkyl, —NR5C(O)NR5R5′, —C(O)NR5R5′, —NR5C(O)R5′, —CN, —NR5SO2R5′, —OC(O)R5, —SO2NR5R5′, —SOR7, —COOH and —C(O)OR7;
R7 for each occurrence is independently selected from the group consisting of C1 to C6 alkyl, aryl and heteroaryl, wherein R7 may optionally be substituted with —(CH2)wOH;
R8 is selected from the group consisting of alkoxy, alkoxycarbonyl, —C(O)NR6R6′, —NR5R5′, —C(O)R6, —NR5C(O)NR5R5′ and —N-heteroaryl;
R9 is selected from the group consisting of heterocycloalkyl, heteroaryl, —CN, —(CH2)pN(R6)C(O)R6′, —(CH2)pCN, —(CH2)pN(R6)C(O)OR6′, —(CH2)pN(R6)C(O)NR6R6′, —(CH2)pN(R6)SO2R6, —(CH2)pC(O)NR6R6′, —(CH2)pC(O)OR6, —(CH2)pOC(O)OR6, —(CH2)pOC(O)R6, —(CH2)pOC(O)NR6R6′, —(CH2)pN(R6)SO2NR6R6′, —(CH2)pOR6, —(CH2)pOC(O)N(R6)(CH2)mOH, —(CH2)pSOR6 and —(CH2)pOCH2C(O)N(R6)(CH2)mOH;
X is selected from the group consisting of —CR5R5′—, —O—, —S—, —SO—, —SO2—, —NC(O)OR7—, —NC(O)NR5— and —NR5—;
m is an integer between 1 and 6;
p is an integer from 0 to 5;
w is an integer between 0 and 5; and
q and s are each independently an integer between 1 and 3,
with the proviso that R5, R5′, R6 or R6′ cannot be hydrogen when either is connected to a carbonyl group or sulfone group.

### Claim 2

A method for increasing muscle mass and/or strength or maintaining muscle strength and function in the elderly which comprises administering a therapeutically effective amount of a compound according to Formula I to a patient in need thereof
wherein
R1 is a substituted or unsubstituted alkyl;
R2 is a substituted or unsubstituted functional group selected from the group consisting of hydrogen, alkyl, aryl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heterocycle, alkoxyalkyl, arylalkyloxyalkyl, aryloxyalkyl, heteroaryl, cycloalkylalkoxyalkyl, heteroarylalkyl and heterocycloalkyl;
R3 and R4 are each independently a substituted or unsubstituted functional group selected from the group consisting of hydrogen and alkyl, or R3 and R4 taken together can form a 4 to 7 membered heterocyclic ring, or one or more of R3 and R4 can be taken together with Y to form a 4 to 7 membered heterocyclic ring;
R1′ is a substituted or unsubstituted functional group selected from the group consisting of hydrogen, alkyl, cycloalkyl, heterocycle, aryl and heteroaryl;
Y is a linking group selected from the group consisting of alkylene, alkenylene, alkynylene, arylene and heteroarylene, said linking group may optionally be substituted with one or more functional group selected from the group consisting of alkyl, aryl, cycloalkyl, heterocycle, alkoxyalkyl, heteroaryl, arylalkyl, arylalkyloxyalkyl, aryloxyalkyl, cycloalkylalkoxyalkyl, heteroarylalkyl, —OR5, —OC(O)R5, —CF3, —OCF3, —N(R5)C(O)R5′ and —NR5R5′;
R5 and R5′ for each occurrence are each independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, heterocycle and aryl, wherein R5 and R5′ for each occurrence may optionally be substituted with one or more Rb;
Rb for each occurrence is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, halogen, cyano, —CN, aryl, arylalkyl, arylalkenyl, arylalkynyl, cycloalkyl, alkoxy, alkoxyalkyl, aryloxy, aryloxyalkyl, heterocycle, heteroaryl, heteroarylalkyl, —OR2, —NR5R5′, —CF3, —SO2R6, —OC(O)R5, —SO2NR6R6′, —(CH2)mR8 and R9;
R6 and R6′ for each occurrence are each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, alkylthioalkyl, alkoxyalkyl, aryl, arylalkyl, heterocycle, heteroaryl, heteroarylalkyl, heterocycloalkyl and cycloalkyl, wherein R6 and R6′ for each occurrence may optionally be substituted with 1 to 3 substituents selected from the group consisting of halogen, OR2, alkoxy, heterocycloalkyl, —NR5C(O)NR5R5′, —C(O)NR5R5′, —NR5C(O)R5′, —CN, —NR5SO2R5′, —OC(O)R5, —SO2NR5R5′, —SOR7, —COOH and —C(O)OR7, or R6 and R6′ taken together can be cyclized to form —(CH2)qX(CH2)s—, which may optionally be substituted with 1 to 3 substituents selected from the group consisting of halogen, OR2, alkoxy, heterocycloalkyl, —NR5C(O)NR5R5′, —C(O)NR5R5′, —NR5C(O)R5′, —CN, —NR5SO2R5′, —OC(O)R5, —SO2NR5R5′, —SOR7, —COOH and —C(O)OR7;
R7 for each occurrence is independently selected from the group consisting of C1 to C6 alkyl, aryl and heteroaryl, wherein R7 may optionally be substituted with —(CH2)wOH;
R8 is selected from the group consisting of alkoxy, alkoxycarbonyl, —C(O)NR6R6′, —NR5R5′, —C(O)R6, —NR5C(O)NR5R5′ and —N-heteroaryl;
R9 is selected from the group consisting of heterocycloalkyl, heteroaryl, —CN, —(CH2)pN(R6)C(O)R6′, —(CH2)pCN, —(CH2)pN(R6)C(O)OR6′, —(CH2)pN(R6)C(O)NR6R6′, —(CH2)pN(R6)SO2R6, —(CH2)pC(O)NR6R6′, —(CH2)pC(O)OR6, —(CH2)pOC(O)OR6, —(CH2)pOC(O)R6, —(CH2)pOC(O)NR6R6′, —(CH2)pN(R6)SO2NR6R6′, —(CH2)pOR6, —(CH2)pOC(O)N(R6)(CH2)mOH, —(CH2)pSOR6 and —(CH2)pOCH2C(O)N(R6)(CH2)mOH;
X is selected from the group consisting of —CR5R5′—, —O—, —S—, —SO—, —SO2—, —NC(O)OR7—, —NC(O)NR5— and —NR5—;
m is an integer between 1 and 6;
p is an integer from 0 to 5;
w is an integer between 0 and 5; and
q and s are each independently an integer between 1 and 3,
with the proviso that R5, R5′, R6 or R6′ cannot be hydrogen when either is connected to a carbonyl group or sulfone group.

### Claim 3

A method of increasing lean body mass which comprises administering a therapeutically effective amount of a compound according to Formula I to a patient in need thereof
wherein
R1 is a substituted or unsubstituted alkyl;
R2 is a substituted or unsubstituted functional group selected from the group consisting of hydrogen, alkyl, aryl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heterocycle, alkoxyalkyl, arylalkyloxyalkyl, aryloxyalkyl, heteroaryl, cycloalkylalkoxyalkyl, heteroarylalkyl and heterocycloalkyl;
R3 and R4 are each independently a substituted or unsubstituted functional group selected from the group consisting of hydrogen and alkyl, or R3 and R4 taken together can form a 4 to 7 membered heterocyclic ring, or one or more of R3 and R4 can be taken together with Y to form a 4 to 7 membered heterocyclic ring;
R1′ is a substituted or unsubstituted functional group selected from the group consisting of hydrogen, alkyl, cycloalkyl, heterocycle, aryl and heteroaryl;
Y is a linking group selected from the group consisting of alkylene, alkenylene, alkynylene, arylene and heteroarylene, said linking group may optionally be substituted with one or more functional group selected from the group consisting of alkyl, aryl, cycloalkyl, heterocycle, alkoxyalkyl, heteroaryl, arylalkyl, arylalkyloxyalkyl, aryloxyalkyl, cycloalkylalkoxyalkyl, heteroarylalkyl, —OR5, —OC(O)R5, —CF3, —OCF3, —N(R5)C(O)R5′ and —NR5R5′;
R5 and R5′ for each occurrence are each independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, heterocycle and aryl, wherein R5 and R5′ for each occurrence may optionally be substituted with one or more Rb;
Rb for each occurrence is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, halogen, cyano, —CN, aryl, arylalkyl, arylalkenyl, arylalkynyl, cycloalkyl, alkoxy, alkoxyalkyl, aryloxy, aryloxyalkyl, heterocycle, heteroaryl, heteroarylalkyl, —OR2, —NR5R5′, —CF3, —SO2R6, —OC(O)R5, —SO2NR6R6′, —(CH2)mR8 and R9;
R6 and R6′ for each occurrence are each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, alkylthioalkyl, alkoxyalkyl, aryl, arylalkyl, heterocycle, heteroaryl, heteroarylalkyl, heterocycloalkyl and cycloalkyl, wherein R6 and R6′ for each occurrence may optionally be substituted with 1 to 3 substituents selected from the group consisting of halogen, OR2, alkoxy, heterocycloalkyl, —NR5C(O)NR5R5′, —C(O)NR5R5′, —NR5C(O)R5′, —CN, —NR5SO2R5′, —OC(O)R5, —SO2NR5R5′, —SOR7, —COOH and —C(O)OR7, or R6 and R6′ taken together can be cyclized to form —(CH2)qX(CH2)s—, which may optionally be substituted with 1 to 3 substituents selected from the group consisting of halogen, OR2, alkoxy, heterocycloalkyl, NR5C(O)NR5R5′, —C(O)NR5R5′, —NR5C(O)R5′, —CN, —NR5SO2R5′, OC(O)R5, —SO2NR5R5′, —SOR7, —COOH and —C(O)OR7;
R7 for each occurrence is independently selected from the group consisting of C1 to C6 alkyl, aryl and heteroaryl, wherein R7 may optionally be substituted with —(CH2)wOH;
R8 is selected from the group consisting of alkoxy, alkoxycarbonyl, —C(O)NR6R6′, —NR5R5′, —C(O)R6, —NR5C(O)NR5R5′ and —N-heteroaryl;
R9 is selected from the group consisting of heterocycloalkyl, heteroaryl, —CN, —(CH2)pN(R6)C(O)R6′, —(CH2)pCN, —(CH2)pN(R6)C(O)OR6′, —(CH2)pN(R6)C(O)NR6R6′, —(CH2)pN(R6)SO2R6, —(CH2)pC(O)NR6R6′, —(CH2)pC(O)OR6, —(CH2)pOC(O)OR6, —(CH2)pOC(O)R6, —(CH2)pOC(O)NR6R6′, —(CH2)pN(R6)SO2NR6R6′, —(CH2)pOR6, —(CH2)pOC(O)N(R6)(CH2)mOH, —(CH2)pSOR6 and —(CH2)pOCH2C(O)N(R6)(CH2)mOH;
X is selected from the group consisting of —CR5R5′—, —O—, —S—, —SO—, —SO2—, —NC(O)OR7—, —NC(O)NR5— and —NR5—;
m is an integer between 1 and 6;
p is an integer from 0 to 5;
w is an integer between 0 and 5; and
q and s are each independently an integer between 1 and 3,
with the proviso that R5, R5′, R6 or R6′ cannot be hydrogen when either is connected to a carbonyl group or sulfone group.

### Claim 4

A method for improving cognitive function which comprises administering a therapeutically effective amount of a compound according to Formula I to a patient in need thereof
wherein
R1 is a substituted or unsubstituted alkyl;
R2 is a substituted or unsubstituted functional group selected from the group consisting of hydrogen, alkyl, aryl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heterocycle, alkoxyalkyl, arylalkyloxyalkyl, aryloxyalkyl, heteroaryl, cycloalkylalkoxyalkyl, heteroarylalkyl and heterocycloalkyl;
R3 and R4 are each independently a substituted or unsubstituted functional group selected from the group consisting of hydrogen and alkyl, or R3 and R4 taken together can form a 4 to 7 membered heterocyclic ring, or one or more of R3 and R4 can be taken together with Y to form a 4 to 7 membered heterocyclic ring;
R1′ is a substituted or unsubstituted functional group selected from the group consisting of hydrogen, alkyl, cycloalkyl, heterocycle, aryl and heteroaryl;
Y is a linking group selected from the group consisting of alkylene, alkenylene, alkynylene, arylene and heteroarylene, said linking group may optionally be substituted with one or more functional group selected from the group consisting of alkyl, aryl, cycloalkyl, heterocycle, alkoxyalkyl, heteroaryl, arylalkyl, arylalkyloxyalkyl, aryloxyalkyl, cycloalkylalkoxyalkyl, heteroarylalkyl, —OR5, —OC(O)R5, —CF3, —OCF3, —N(R5)C(O)R5′ and —NR5R5′;
R5 and R5′ for each occurrence are each independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, heterocycle and aryl, wherein R5 and R5′ for each occurrence may optionally be substituted with one or more Rb;
Rb for each occurrence is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, halogen, cyano, —CN, aryl, arylalkyl, arylalkenyl, arylalkynyl, cycloalkyl, alkoxy, alkoxyalkyl, aryloxy, aryloxyalkyl, heterocycle, heteroaryl, heteroarylalkyl, —OR2, —NR5R5′, —CF3, —SO2R6, —OC(O)R5, —SO2NR6R6′, —(CH2)mR8 and R9;
R6 and R6′ for each occurrence are each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, alkylthioalkyl, alkoxyalkyl, aryl, arylalkyl, heterocycle, heteroaryl, heteroarylalkyl, heterocycloalkyl and cycloalkyl, wherein R6 and R6′ for each occurrence may optionally be substituted with 1 to 3 substituents selected from the group consisting of halogen, OR2, alkoxy, heterocycloalkyl, —NR5C(O)NR5R5′, —C(O)NR5R5′, —NR5C(O)R5′, —CN, —NR5SO2R5′, —OC(O)R5, —SO2NR5R5′, —SOR7, —COOH and —C(O)OR7, or R6 and R6′ taken together can be cyclized to form —(CH2)qX(CH2)s—, which may optionally be substituted with 1 to 3 substituents selected from the group consisting of halogen, OR2, alkoxy, heterocycloalkyl, —NR5C(O)NR5R5′, —C(O)NR5R5′, —NR5C(O)R5′, —CN, —NR5SO2R5′, —OC(O)R5, —SO2NR5R5′, —SOR7, —COOH and —C(O)OR7;
R7 for each occurrence is independently selected from the group consisting of C1 to C6 alkyl, aryl and heteroaryl, wherein R7 may optionally be substituted with —(CH2)wOH;
R8 is selected from the group consisting of alkoxy, alkoxycarbonyl, —C(O)NR6R6′, —NR5R5′, —C(O)R6, —NR5C(O)NR5R5′ and —N-heteroaryl;
R9 is selected from the group consisting of heterocycloalkyl, heteroaryl, —CN, —(CH2)pN(R6)C(O)R6′, —(CH2)pCN, —(CH2)pN(R6)C(O)OR6′, —(CH2)pN(R6)C(O)NR6R6′, —(CH2)pN(R6)SO2R6, —(CH2)pC(O)NR6R6′, —(CH2)pC(O)OR6, —(CH2)pOC(O)OR6, —(CH2)pOC(O)R6, —(CH2)pOC(O)NR6R6′, —(CH2)pN(R6)SO2NR6R6′, —(CH2)pOR6, —(CH2)pOC(O)N(R6)(CH2)mOH, —(CH2)pSOR6 and —(CH2)pOCH2C(O)N(R6)(CH2)mOH;
X is selected from the group consisting of —CR5R5′—, —O—, —S—, —SO—, —SO2—, —NC(O)OR7—, —NC(O)NR5— and —NR5—;
m is an integer between 1 and 6;
p is an integer from 0 to 5;
w is an integer between 0 and 5; and
q and s are each independently an integer between 1 and 3,
with the proviso that R5, R5′, R6 or R6′ cannot be hydrogen when either is connected to a carbonyl group or sulfone group.

### Claim 5

A method for improving the immune response to vaccination which comprises administering a therapeutically effective amount of a compound according to Formula I to a patient in need thereof
wherein
R1 is a substituted or unsubstituted alkyl;
R2 is a substituted or unsubstituted functional group selected from the group consisting of hydrogen, alkyl, aryl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heterocycle, alkoxyalkyl, arylalkyloxyalkyl, aryloxyalkyl, heteroaryl, cycloalkylalkoxyalkyl, heteroarylalkyl and heterocycloalkyl;
R3 and R4 are each independently a substituted or unsubstituted functional group selected from the group consisting of hydrogen and alkyl, or R3 and R4 taken together can form a 4 to 7 membered heterocyclic ring, or one or more of R3 and R4 can be taken together with Y to form a 4 to 7 membered heterocyclic ring;
R1′ is a substituted or unsubstituted functional group selected from the group consisting of hydrogen, alkyl, cycloalkyl, heterocycle, aryl and heteroaryl;
Y is a linking group selected from the group consisting of alkylene, alkenylene, alkynylene, arylene and heteroarylene, said linking group may optionally be substituted with one or more functional group selected from the group consisting of alkyl, aryl, cycloalkyl, heterocycle, alkoxyalkyl, heteroaryl, arylalkyl, arylalkyloxyalkyl, aryloxyalkyl, cycloalkylalkoxyalkyl, heteroarylalkyl, —OR5, —OC(O)R5, —CF3, —OCF3, —N(R5)C(O)R5′ and —NR5R5′;
R5 and R5′ for each occurrence are each independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, heterocycle and aryl, wherein R5 and R5′ for each occurrence may optionally be substituted with one or more Rb;
Rb for each occurrence is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, halogen, cyano, —CN, aryl, arylalkyl, arylalkenyl, arylalkynyl, cycloalkyl, alkoxy, alkoxyalkyl, aryloxy, aryloxyalkyl, heterocycle, heteroaryl, heteroarylalkyl, —OR2, —NR5R5′, —CF3, —SO2R6, —OC(O)R5, —SO2NR6R6′, —(CH2)mR8 and R9;
R6 and R6′ for each occurrence are each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, alkylthioalkyl, alkoxyalkyl, aryl, arylalkyl, heterocycle, heteroaryl, heteroarylalkyl, heterocycloalkyl and cycloalkyl, wherein R6 and R6′ for each occurrence may optionally be substituted with 1 to 3 substituents selected from the group consisting of halogen, OR2, alkoxy, heterocycloalkyl, —NR5C(O)NR5R5′, —C(O)NR5R5′, —NR5C(O)R5′, —CN, —NR5SO2R5′, —OC(O)R5, —SO2NR5R5′, —SOR7, —COOH and —C(O)OR7, or R6 and R6′ taken together can be cyclized to form —(CH2)qX(CH2)s—, which may optionally be substituted with 1 to 3 substituents selected from the group consisting of halogen, OR2, alkoxy, heterocycloalkyl, NR5C(O)NR5R5′, —C(O)NR5R5′, —NR5C(O)R5′, —CN, —NR5SO2R5′, —OC(O)R5, —SO2NR5R5′, —SOR7, —COOH and —C(O)OR7;
R7 for each occurrence is independently selected from the group consisting of C1 to C6 alkyl, aryl and heteroaryl, wherein R7 may optionally be substituted with —(CH2)wOH;
R8 is selected from the group consisting of alkoxy, alkoxycarbonyl, —C(O)NR6R6′, —NR5R5′, —C(O)R6, —NR5C(O)NR5R5′ and —N-heteroaryl;
R9 is selected from the group consisting of heterocycloalkyl, heteroaryl, —CN, —(CH2)pN(R6)C(O)R6′, —(CH2)pCN, —(CH2)pN(R6)C(O)OR6′, —(CH2)pN(R6)C(O)NR6R6′, —(CH2)pN(R6)SO2R6, —(CH2)pC(O)NR6R6′, —(CH2)pC(O)OR6, —(CH2)pOC(O)OR6, —(CH2)pOC(O)R6, —(CH2)pOC(O)NR6R6′, —(CH2)pN(R6)SO2NR6R6′, —(CH2)pOR6, —(CH2)pOC(O)N(R6)(CH2)mOH, —(CH2)pSOR6 and —(CH2)pOCH2C(O)N(R6)(CH2)mOH;
X is selected from the group consisting of —CR5R5′—, —O—, —S—, —SO—, —SO2—, —NC(O)OR7—, —NC(O)NR5— and —NR5—;
m is an integer between 1 and 6;
p is an integer from 0 to 5;
w is an integer between 0 and 5; and
q and s are each independently an integer between 1 and 3,
with the proviso that R5, R5′, R6 or R6′ cannot be hydrogen when either is connected to a carbonyl group or sulfone group.

### Claim 6

A method for accelerating the recovery of hip fracture which comprises administering a therapeutically effective amount of a compound according to Formula I to a patient in need thereof
wherein
R1 is a substituted or unsubstituted alkyl;
R2 is a substituted or unsubstituted functional group selected from the group consisting of hydrogen, alkyl, aryl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heterocycle, alkoxyalkyl, arylalkyloxyalkyl, aryloxyalkyl, heteroaryl, cycloalkylalkoxyalkyl, heteroarylalkyl and heterocycloalkyl;
R3 and R4 are each independently a substituted or unsubstituted functional group selected from the group consisting of hydrogen and alkyl, or R3 and R4 taken together can form a 4 to 7 membered heterocyclic ring, or one or more of R3 and R4 can be taken together with Y to form a 4 to 7 membered heterocyclic ring;
R1′ is a substituted or unsubstituted functional group selected from the group consisting of hydrogen, alkyl, cycloalkyl, heterocycle, aryl and heteroaryl;
Y is a linking group selected from the group consisting of alkylene, alkenylene, alkynylene, arylene and heteroarylene, said linking group may optionally be substituted with one or more functional group selected from the group consisting of alkyl, aryl, cycloalkyl, heterocycle, alkoxyalkyl, heteroaryl, arylalkyl, arylalkyloxyalkyl, aryloxyalkyl, cycloalkylalkoxyalkyl, heteroarylalkyl, —OR5, —OC(O)R5, —CF3, —OCF3, —N(R5)C(O)R5′ and —NR5R5′;
R5 and R5′ for each occurrence are each independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, heterocycle and aryl, wherein R5 and R5′ for each occurrence may optionally be substituted with one or more Rb;
Rb for each occurrence is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, halogen, cyano, —CN, aryl, arylalkyl, arylalkenyl, arylalkynyl, cycloalkyl, alkoxy, alkoxyalkyl, aryloxy, aryloxyalkyl, heterocycle, heteroaryl, heteroarylalkyl, —OR2, —NR5R5′, —CF3, —SO2R6, —OC(O)R5, —SO2NR6R6′, —(CH2)mR8 and R9;
R6 and R6′ for each occurrence are each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, alkylthioalkyl, alkoxyalkyl, aryl, arylalkyl, heterocycle, heteroaryl, heteroarylalkyl, heterocycloalkyl and cycloalkyl, wherein R6 and R6′ for each occurrence may optionally be substituted with 1 to 3 substituents selected from the group consisting of halogen, OR2, alkoxy, heterocycloalkyl, —NR5C(O)NR5R5′, —C(O)NR5R5′, —NR5C(O)R5′, —CN, —NR5SO2R5′, —OC(O)R5, —SO2NR5R5′, —SOR7, —COOH and —C(O)OR7, or R6 and R6′ taken together can be cyclized to form —(CH2)qX(CH2)s—, which may optionally be substituted with 1 to 3 substituents selected from the group consisting of halogen, OR2, alkoxy, heterocycloalkyl, —NR5C(O)NR5R5′, —C(O)NR5R5′, —NR5C(O)R5′, —CN, —NR5SO2R5′, —OC(O)R5, —SO2NR5R5′, —SOR7, —COOH and —C(O)OR7;
R7 for each occurrence is independently selected from the group consisting of C1 to C6 alkyl, aryl and heteroaryl, wherein R7 may optionally be substituted with —(CH2)wOH;
R8 is selected from the group consisting of alkoxy, alkoxycarbonyl, —C(O)NR6R6′, —NR5R5′, —C(O)R6, —NR5C(O)NR5R5′ and —N-heteroaryl;
R9 is selected from the group consisting of heterocycloalkyl, heteroaryl, —CN, —(CH2)pN(R6)C(O)R6′, —(CH2)pCN, —(CH2)pN(R6)C(O)OR6′, —(CH2)pN(R6)C(O)NR6R6′, —(CH2)pN(R6)SO2R6, —(CH2)pC(O)NR6R6′, —(CH2)pC(O)OR6, —(CH2)pOC(O)OR6, —(CH2)pOC(O)R6, —(CH2)pOC(O)NR6R6′, —(CH2)pN(R6)SO2NR6R6′, —(CH2)pOR6, —(CH2)pOC(O)N(R6)(CH2)mOH, —(CH2)pSOR6 and —(CH2)pOCH2C(O)N(R6)(CH2)mOH;
X is selected from the group consisting of —CR5R5′—, —O—, —S—, —SO—, —SO2—, —NC(O)OR7—, —NC(O)NR5— and —NR5—;
m is an integer between 1 and 6;
p is an integer from 0 to 5;
w is an integer between 0 and 5; and
q and s are each independently an integer between 1 and 3,
with the proviso that R5, R5′, R6 or R6′ cannot be hydrogen when either is connected to a carbonyl group or sulfone group.
